Titre:
  • Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases.
Auteur:Beuselinck, B; Wolter, P; Karadimou, A; Elaidi, R; Dumez, Herlinde; Rogiers, Annick; Van Cann, T; Willems, L; Body, Jean-Jacques; Berkers, J; Van Poppel, H; Lerut, E; Debruyne, P; Paridaens, R; Schöffski, P
Informations sur la publication:British Journal of Cancer, 107, 10, page (1665-1671)
Statut de publication:Publié, 2012-11
Sujet CREF:Sciences bio-médicales et agricoles
Mots-clés:Bisphosphonates
Bone metastases
Osteonecrosis of the jaw
Outcome
Renal cell carcinoma
Targeted therapy
MeSH keywords:Antineoplastic Combined Chemotherapy Protocols -- adverse effects -- therapeutic use
Bone Density Conservation Agents -- administration & dosage -- adverse effects
Bone Neoplasms -- drug therapy -- pathology -- secondary
Carcinoma, Renal Cell -- drug therapy -- pathology -- secondary
Diphosphonates -- administration & dosage -- adverse effects
Disease-Free Survival
Female
Humans
Indoles -- administration & dosage
Kidney Neoplasms -- drug therapy -- pathology
Male
Middle Aged
Neoplasm Metastasis
Niacinamide -- administration & dosage -- analogs & derivatives
Osteonecrosis -- chemically induced
Phenylurea Compounds -- administration & dosage
Prognosis
Protein Kinase Inhibitors -- administration & dosage
Protein-Tyrosine Kinases -- antagonists & inhibitors
Pyrroles -- administration & dosage
Retrospective Studies
Treatment Outcome
Note générale:Journal Article
Research Support, Non-U.S. Gov't
SCOPUS: ar.j
Langue:Anglais
Identificateurs:urn:issn:0007-0920
info:doi/10.1038/bjc.2012.385
info:pii/bjc2012385
info:scp/84869225968
info:pmid/23132391